WuXi Biologics (Cayman) Inc. - SIC # 8922 -

Ticker Exchange SIC # Website Latest Ticker
WXXWY Over the counter 8922 www.wuxibiologics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for WuXi Biologics (Cayman) Inc.

Is WuXi Biologics (SEHK:2269) Still Attractively Priced After Its 121% One Year Rebound - Jan 16th, 2026 12:09 pm
JPM26: Bi- and multispecific modalities power Wuxi Biologics growth - Jan 15th, 2026 4:32 am
JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth - Jan 14th, 2026 9:00 pm
WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic - Jan 12th, 2026 8:06 pm
WuXi Biologics Launches Industry-Leading Digital Twin Platform PatroLab™ Designed to Transform Bioprocessing and Manufacturing - Jan 12th, 2026 6:09 am
Assessing WuXi Biologics (SEHK:2269) Valuation After New Sustainable Procurement Certification - Jan 7th, 2026 4:14 pm
WuXi Biologics Achieves ISO 20400 Certification, Setting Benchmark in Sustainable Procurement - Jan 4th, 2026 8:57 pm
WuXi Biologics Recognized by Hong Kong ESG Reporting Awards 2025 for Outstanding ESG Disclosure - Dec 23rd, 2025 9:30 pm
WuXi Biologics Achieves CDP Highest "A" Ratings in Both Climate Change and Water Security - Dec 19th, 2025 2:30 am
WuXi Biologics Extends Global CRDMO Network to Qatar Through Strategic MoU Signed with Qatar Free Zones Authority - Dec 2nd, 2025 1:46 am
WuXi Biologics (SEHK:2269): Exploring Valuation After Recent Turnaround in Share Price Momentum - Nov 11th, 2025 3:13 pm
Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London - Nov 11th, 2025 6:00 am
WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index - Oct 21st, 2025 6:30 pm
WuXi Biologics Honored with 2025 Global Customer Value Leadership Recognition by Frost & Sullivan - Oct 20th, 2025 3:30 am
WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year - Oct 9th, 2025 6:30 pm
WuXi Biologics (SEHK:2269) Valuation in Focus Following Recent Share Price Gains - Oct 4th, 2025 7:47 am
The 2025 BPD Singapore Conference Has Concluded Successfully! Jointly Embarking on a New Journey for Global Development - Sep 26th, 2025 7:00 pm
WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™，to Accelerate Biologics Development with High Titer and Superior Stability - Sep 25th, 2025 5:42 am
WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year - Sep 22nd, 2025 10:00 pm
Three WuXi Biologics Manufacturing Facilities Receive GMP Certification from Türkiye İlaç ve Tıbbi Cihaz Kurumu (TITCK) - Sep 16th, 2025 10:00 pm